Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 4Sarcoma 1Gynecologic 1

Conditions

Gastrointestinal Stromal Tumors 15Neoplasms 3Sarcoma 1Retroperitoneal liposarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Piebaldism 1Neoplasm Metastasis 1Liposarcoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leiomyosarcoma 1Gastrointestinal Neoplasms 1Disease Progression 1Chordoma 1Chondrosarcoma 1

Interventions

pembrolizumab 11Gemcitabine 10Doxorubicin 10Cyclophosphamide 9Specimen Handling 8Nivolumab 8Ibandronic Acid 8pazopanib 7Radiosurgery 6Magnetic Resonance Spectroscopy 6Imatinib Mesylate 6Biopsy 6Bevacizumab 6Irinotecan 5regorafenib 4Zoledronic Acid 4Ipilimumab 4Ifosfamide 4Fluorouracil 4Docetaxel 4Cetuximab 4sargramostim 3conatumumab 3cemiplimab 3Sunitinib 3Radiation 3Paclitaxel 3Leucovorin 3Cryosurgery 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × nilotinib × Sarcoma × Clear all
NCT03784014 2026-04-29

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Completed
603 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡